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Abstract
Background: Sorafenib, an oral multikinase inhibitor, has anti-proliferative and anti-angiogenic activities and is
therapeutically effective against renal cell carcinoma (RCC). Recently, we have evaluated the tumor responses to
sorafenib treatment in a RCC xenograft using [Methyl-3H(N)]-3′-fluoro-3′-deoxythythymidine ([3H]FLT). Contrary to
our expectation, the FLT level in the tumor significantly increased after the treatment. In this study, to clarify the
reason for the elevated FLT level, dynamic 3′-[18F]fluoro-3′-deoxythymidine ([18F]FLT) positron emission tomography
(PET) and kinetic studies were performed in mice bearing a RCC xenograft (A498).
The A498 xenograft was established in nude mice, and the mice were assigned to the control (n = 5) and treatment
(n = 5) groups. The mice in the treatment group were orally given sorafenib (20 mg/kg/day p.o.) once daily for
3 days. Twenty-four hours after the treatment, dynamic [18F]FLT PET was performed by small-animal PET. Three-
dimensional regions of interest (ROIs) were manually defined for the tumors. A three-compartment model fitting
was carried out to estimate four rate constants using the time activity curve (TAC) in the tumor and the blood
clearance rate of [18F]FLT.
Results: The dynamic pattern of [18F]FLT levels in the tumor significantly changed after the treatment. The rate
constant of [18F]FLT phosphorylation (k3) was significantly higher in the treatment group (0.111 ± 0.027 [1/min])
than in the control group (0.082 ± 0.009 [1/min]). No significant changes were observed in the distribution volume,
the ratio of [18F]FLT forward transport (K1) to reverse transport (k2), between the two groups (0.556 ± 0.073 and 0.
641 ± 0.052 [mL/g] in the control group).
Conclusions: Our dynamic PET studies indicated that the increase in FLT level may be caused by the
phosphorylation of FLT in the tumor after the sorafenib treatment in the mice bearing a RCC xenograft. Dynamic
PET studies with kinetic modeling could provide improved understanding of the biochemical processes involved in
tumor responses to therapy.
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Background
Tumor proliferation is a hallmark of the cancer pheno-
type and is one of the useful markers for evaluating the
therapeutic effect and prognosis after conventional ther-
apy in clinical oncology. Positron emission tomography
(PET) using 3′-[18F]fluoro-3′-deoxythymidine ([18F]FLT)
is one of the noninvasive methods of assessing tumor
proliferation [1–3]. Accordingly, we have recently evalu-
ated the tumor responses to sorafenib treatment in our
model experiments using a renal cell carcinoma (RCC)
xenograft and [methyl-3H(N)]-3′-fluoro-3′-deoxythythy-
midine ([3H]FLT) [4]. Sorafenib is a multikinase inhibitor
that has anti-proliferative and anti-angiogenic activities
and is reported to show significant therapeutic effects
against RCC [5, 6]. Contrary to our expectation, however,
the level of [3H]FLT in the tumor significantly increased
after the sorafenib treatment [4].
Including in our previous study [4], static parameters
such as standardized uptake value (SUV) have been ex-
tensively used to monitor treatment-induced changes in
oncology [7–10]. PET is, however, a dynamic imaging
modality that allows the imaging and observation of the
distribution of a radiolabeled tracer throughout the body
over time [11–15]. Therefore, tracer kinetic modeling
techniques with PET have been widely used in neurology
and cardiology to study biochemical and physiological
processes in humans and small animals. Application of
the kinetic modeling techniques could also provide im-
proved understanding of the complex biochemical pro-
cesses involved in tumor responses to therapy. Accordingly,
in this study, to clarify the reason for the elevated FLT
level after sorafenib treatment, we applied the kinetic
modeling techniques and evaluated the dynamic pat-
terns of [18F]FLT level in the tumors of the mice bear-
ing a RCC xenograft (A498).
Methods
Radiopharmaceuticals
[18F]FLT was obtained from the Hokkaido University
Hospital Cyclotron Facility, which was synthesized by
standard procedures [16].
Animal models
The entire experimental protocols were approved by the
Laboratory Animal Care and Use Committee of Hokkaido
University (approval number 13-0057) and performed in
accordance with the Guidelines for Animal Experiments
at the Graduate School of Medicine, Hokkaido University.
Eight-week-old male BALB/c athymic nude mice were
supplied by Japan SLC, Inc. (Hamamatsu, Japan) and used
in all experiments. The room temperature was maintained
between 23 and 25 °C, and the relative humidity was
maintained between 45 and 60%. The institutional labora-
tory housing provided a 12-h light/dark cycle and met all
the criteria of the Association for Assessment and Ac-
creditation of Laboratory Animal Care (AAALAC) Inter-
national. A RCC xenograft model was established using a
human clear cell RCC (A498) cell line (European Collec-
tion of Cell Cultures, Salisbury, UK). A489 cells were
maintained in RPMI-1640 medium (Invitrogen/Thermo
Fisher Scientific, Inc., Carlsbad, CA, USA); supplemented
with 10% fetal bovine serum, penicillin–streptomycin, and
0.03% glutamine; and incubated in an atmosphere of 5%
CO2 and 95% air at 37 °C. A498 cells (1 × 10
7 cells/
0.1 mL) were subcutaneously inoculated into the right
dorsal area of each mouse. When the tumors grew 12–
13 mm in diameter, the mice were assigned to the control
(n = 5) and sorafenib-treated (n = 5) groups. The mice in
the sorafenib-treated group were administered sorafenib
(20 mg/kg/day p.o.; Nexavar, Bayer Pharmaceuticals
Corporation, West Haven, CT, USA) once daily for 3 days.
The vehicle was administered to the control group [4].
PET study
Twenty-four hours after the last treatment to reproduce
the experimental conditions with our previous study [4, 17]
and to prevent the acute influence after the treatment, we
performed dynamic [18F]FLT PET using a small-animal
multimodality system (Inveon, Siemens Medical Solutions,
Knoxville, TN). The PET component consists of 1.5 × 1.5 ×
10 mm3 lutetium oxyorthosilicate crystal elements with a
ring diameter of 16.1 cm, to give an effective transaxial field
of view (FOV) of 10 cm and an axial FOV of 12.7 cm. CT
was also performed for attenuation correction. The mice
were maintained under anesthesia with 1.0–1.5% isoflurane
and placed on a heating sheet during scanning. Dynamic
(list-mode) [18F]FLT PET was performed up to 120 min
after the injection with [18F]FLT (7.63 ± 1.87 MBq bolus via
the tail vein). The images were reconstructed and corrected
for attenuation and scattered using the Fourier rebinning
algorithm and filtered back projection with the ramp filter
cut-off at the Nyquist frequency. The image matrix was
128 × 128 × 159, resulting in a voxel size of 0.776 ×
0.776 × 0.796 mm3. The 120-min list-mode data were
used in the following sequence: eight 15-s, three 60-s,
five 5-min, and nine 10-min time frames. The spatial
resolution of reconstructed images was 1.63 mm at full
width at half maximum [18].
Data analysis
Kinetic analysis
Images were analyzed using the Inveon Research Work-
place 4.2. A three- dimensional region of interest (ROI)
was manually defined in each mouse for the tumor
using the last time frame (110–120 min) of the PET
image with a threshold of one-half of the maximum
SUV of the tumor. The tumor ROI was automatically
copied to every dynamic image to obtain time activity
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curves (TACs). SUV was calculated from the last time
frame (110–120 min) of the PET image using the fol-
lowing equation.
SUV ¼ activity in a 3D tumor ROI Bq=mLð Þ
injection dose Bqð Þ=body weight gð Þ
A cuboid ROI (1.5 × 1.5 × 2.0 mm3) was drawn on the
left ventricle (LV) region on a CT image and projected
to every PET image to obtain TACs of [18F]FLT in the
blood (Fig. 1a–d), which was used as the input function
for the modeling analysis [19].
A three-compartment model fitting (Fig. 2) was carried
out to estimate four rate constants using the TACs of
the tumor and the blood [11, 20, 21]. The rate constants
of the model represent the forward transport of [18F]FLT
from blood to tissue (K1), the reverse transport (k2), the
phosphorylation of [18F]FLT (k3), and the dephosphory-
lation (k4) [20]. The early distribution volume (Vd) of
[18F]FLT in tissue was also defined as K1/k2. The kinetic
imaging system (KIS), which is an Internet-based kinetic
simulation and model fitting program, was used to esti-
mate the values of the rate constants [22]. Correction on
the blood volume fraction was included in the modeling
of this system. The blood volume was fixed at 0.03
[mL/g]. The amounts of [18F]FLT metabolites in the
blood were minuscule [23].
Statistical analysis
Repeated measures analysis of variance (ANOVA) was
carried out to assess the differences in TACs between
the control and the sorafenib-treated groups. The SUVs
of [18F]FLT in the tumors and each rate constant were
compared using the unpaired t test between the control
and sorafenib-treated groups. A two-tailed value of
p < 0.05 was considered significant.
Results
Figures 1a, b shows the blood clearance curves of the
control and sorafenib-treated groups, respectively, which
were obtained from the SUVs in the cuboid ROI
placed on the LV region (Fig. 1d). There were no sig-
nificant differences in the input function between the
two groups (Fig. 1c).
The tumor TACs are shown in Fig. 3. In the control
group, the tumor TAC peaked immediately after the in-
jection and then decreased (Fig. 3a, c). In the sorafenib-
treated group, the tumor TAC gradually increased with
time and reached a plateau (Fig. 3b, c). The dynamic
patterns of the tumor [18F]FLT level were significantly
Fig. 1 Blood time activity curves (input function) for [18F]FLT in the left ventricle. a Control group. b Sorafenib-treated group. c Average of each
group (SUV ± SD). d Transaxial image of [18F]FLT PET across the heart of the mouse at first flame (0–15 s). A cuboid ROI (1.5 × 1.5 × 2.0 mm3) was
drawn on the left ventricle (LV) region on a CT image and projected to every PET image to obtain the LV TAC (filled blue region)
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different between the control and sorafenib-treated
groups (p < 0.05).
The rate constants (K1, k2, k3, and k4) and the Vd
(K1/k2) are summarized in Table 1. K1, k2, and k4
were significantly lower in the sorafenib-treated
group than in the control group. k3 was signifi-
cantly higher in the sorafenib-treated group than in
the control group. No significant changes were ob-
served in Vd between the control and sorafenib-
treated groups.
Figure 4a, b shows PET images of [18F]FLT (horizontal
sections) at 110–120 min postinjection in the mice
bearing the tumor. The images clearly show higher
radioactivity levels in the tumor regions of the treated
mice than those of the control mice. Figure 4c shows
the SUVs of [18F]FLT in the tumor of the control
(0.602 ± 0.216) and sorafenib-treated (1.653 ± 0.309)
groups. The SUVs in the tumor of the sorafenib-treated
group were significantly higher than those of the
control group (Figs. 3 and 4).
Fig. 2 Compartment model of [18F]FLT in the tumor tissue. K1, k2, k3, and k4 are the kinetic rate constants between the compartments. Cp blood
concentration of [18F]FLT, Ce exchangeable [18F]FLT concentration in the tissue, Cm phosphorylated [18F]FLT metabolites in the tissue, Cmet
concentration of [18F]FLT metabolites in the arterial plasma. FLTMP FLT-monophosphate, TLTDP FLT-diphosphate, FLTTP FLT-triphosphate,
FLT-gluc FLT-glucuronide
Fig. 3 Time activity curves in the tumor following [18F]FLT injection. a Control group. b Sorafenib-treated group. c Average of each group (SUV ± SD)
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Discussion
In this study, to clarify the reason for the elevated FLT
level after sorafenib treatment, which was observed in
our previous study [4], we evaluated the dynamic pat-
terns of the [18F]FLT level in the tumors by PET. k3,
which indicates the extent of phosphorylation, was
significantly higher in the sorafenib-treated group than
in the control group. It is suggested that the increase in
the FLT level may be caused by FLT phosphorylation in
the tumor after sorafenib treatment.
In this study, we investigated the kinetics of [18F]FLT in
the RCC tumor and estimated the rate constants (K1, k2, k3,
and k4). The forward transport (K1) and reverse transport
(k2) were significantly higher in the control group (Table 1).
Sorafenib has an anti-angiogenic property; the decrease in
vessel density after sorafenib treatment, as shown in our
previous histological experiment [24], may reduce the blood
flow, resulting in the decrease in K1 and k2 values. However,
no significant changes were observed in the Vd (K1/k2)
between the two groups, suggesting that the change in the
blood flow may not affect the accumulation of FLT in the
tumor. The higher rate constant k3 in the sorafenib-treated
group suggests the increased phosphorylation of FLT, which
might cause the increased retention of FLT in the tumor.
Dephosphorylation may also be responsible for the
retention of FLT in the tumor because k4 is decreased.
Table 1 Estimated compartment model parameters
K1 (mL/min/g) k2 (1/min) k3 (1/min) k4 (1/min) Vd (mL/g)
Control 0.547 ± 0.106 1.012 ± 0.284 0.082 ± 0.009 0.037 ± 0.006 0.556 ± 0.073
Sorafenib 0.231 ± 0.050 0.359 ± 0.060 0.111 ± 0.027 0.017 ± 0.003 0.641 ± 0.052
p value <0.01 <0.01 <0.05 <0.01 N.S.
Fig. 4 PET images of [18F]FLT (horizontal sections) at 110–120 min postinjection in the mice bearing the tumor. a Control group. b Sorafenib-treated
group. Filled arrows show the tumor region and blank arrows show the bladder. Artifacts due to extremely high radioactivity accumulation were
observed in the bladder area. c SUVs of [18F]FLT in the tumor at 110–120 min postinjection
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Note that the increase in FLT level was inconsistent
with the Ki-67 index, which can be used to evaluate the
tumor proliferation in our previous study [4]. Recent
studies have revealed the discordance between FLT level
and other tumor proliferation markers, for example, Ki-
67 index [25, 26]. It is also reported that FLT level does
not reflect tumor proliferation but TK1 activity [26–28].
The increase in FLT uptake level is caused by the upreg-
ulation of TK-1 activity without an increase in the level
of proliferation markers. The present results strongly in-
dicate that the increase in FLT level after sorafenib treat-
ment may be caused by the phosphorylation of FLT.
Accordingly, one of the potential causes of the increase
in FLT level is the upregulation of TK1 activity that
arises from the inhibition of thymidylate synthase (TS).
Several studies have shown that FLT uptake level reflects
TS inhibition by fluorouracil (5-FU) treatment inde-
pendent of tumor proliferation changes [29–31]. There
are two pathways of thymidine supply for DNA synthe-
sis, the de novo pathway and the salvage pathway. TS
and TK1 are critical enzymes in the de novo and salvage
pathways, respectively. When the de novo pathway is
suppressed, the salvage pathway is upregulated to com-
pensate for this suppression and maintain a certain level
of thymidine supply [31, 32]. Thus, TS inhibition or
suppression may increase TK1 activity and FLT uptake
level [31]. Regarding the effect of sorafenib on the thy-
midine supply pathways, only one study has suggested
the suppression of TS in RCC cells following sorafenib
treatment [33]. The increase in FLT uptake level follow-
ing sorafenib treatment in the present study may have
been caused by the TS suppressive effect of sorafenib
and the subsequent upregulation of the thymidine
salvage pathway.
Our studies also revealed the need for further studies.
Analyses of metabolites including phosphorylated FLT in
the tumors of control and sorafenib-treated groups may
clarify the factors responsible for the increase in FLT
level after sorafenib treatment. Evaluation at various
time points after sorafenib treatment, particularly long-
term observations, will provide additional information
on the tumor responses after the treatment.
It should be noted here that there have been several re-
ports on PET studies using [18F]FLT and rodents [34, 35].
Honndorf et al. [34] monitored the impact of genistein
therapy using the two PET tracers [18F]FDG and [18F]FLT
in vivo in two xenograft mouse models. Rapic et al. [35]
investigated the early effects of chemotherapeutic tre-
atment on cancer cell proliferation in a BRAF-mutated
colorectal cancer using [18F]FLT. These studies focused
on the correlation of FLT level and tumor response [3]. In
the present study, we evaluated the dynamic patterns of
the [18F]FLT level in the tumors, to clarify the reason for
the elevated FLT level after sorafenib treatment. To date,
there have only been limited studies of the therapeutic
effect of radiation therapy and chemotherapy on tumor
using dynamic PET and compartment model analysis
[21, 36, 37]. Moreover, such studies exclusively used
FDG in clinical settings. For example, Nishiyama et al.
[36] investigated the accumulation of FDG in primary
central nervous system (CNS) lymphoma using dynamic
PET images and compared with baseline and follow-up
kinetic parameters after chemoradiotherapy. They showed
that the kinetic analysis, especially with respect to k3, might
be helpful for monitoring therapeutic assessment. To the
best of our knowledge, FLT and kinetic modeling tech-
niques have been utilized to evaluate tumor responses to
therapy in a few clinical studies [38–40] and only one
experimental study [21]. Pan et al. [21] investigated the
change in the rate of cell proliferation in a murine tumor
model after radiation therapy using [18F]FLT and evaluated
the sensitivity of kinetic analysis over semiquantitative
measures for monitoring radiation responses. They showed
the kinetics of the [18F]FLT level and kinetic parameters in
the mammary carcinoma cell line, which were altered
treatment-dependently 1 day after radiation therapy. In this
study, we first applied kinetic analysis and dynamic FLT
PET for assessing the tumor responses to molecular-
targeted therapy in animal models and succeeded in clarify-
ing the reason for the increase in FLT level after sorafenib
treatment. Thus, kinetic analysis and dynamic FLT PET
should be useful for assessing the biochemical processes
involved in tumor responses to therapy.
There are limitations in this study. ROIs were defined
on the LV chamber region to obtain the input function.
The LV ROIs were small, and therefore, the input func-
tions may be underestimated due to the partial volume
effects (PVEs). The PVEs due to the sizes of the tumor
and LV were not corrected in the present study. It may
be important to consider the PVEs on our results. The
PVEs, however, do not appear to largely affect the com-
parison of the kinetic parameters between the control
and sorafenib-treated mice, as the similar kinetic analysis
was performed in both of the groups.
It is important to consider whether similar effects can be
obtained even in human studies. Zhang et al. treated the
mice bearing human RCC (A498) xenografts with sorafenib
[41]. In these experiments, they were able to demonstrate
the responses to sorafenib, re-induction of tumor necrosis
and associated reduction in tumor perfusion, which were
relevant to clinical situation. The results may suggest the
relevance of our study in A498 model mice to human stud-
ies partly although further studies to clarify whether our
results are actually general or not are necessary.
Conclusions
The dynamic pattern of [18F]FLT uptake level in the
tumor was significantly changed after sorafenib treatment.
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The rate constant k3, representing FLT phosphorylation,
significantly increased after sorafenib treatment, whereas
the distribution volume did not change. These findings
indicate that the increase in FLT level may be caused by
FLT phosphorylation in the tumor after sorafenib treat-
ment in the mice bearing a RCC xenograft. Dynamic PET
studies with kinetic modeling could provide improved
understanding of the biochemical processes involved in
tumor responses to therapy.
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